Clinical Trials29 Jul 2022 10:30
The CT website, last updated June 2nd, identifies the Primary outcome measures on safety and the secondary outcome measures on immunogenicity with the same completion dates of between 6 and 26 weeks.
It also shows that âthe studyâ commenced on October 1st 2021
From the Clinical Trials website
â Participants enrolled under the initial protocol (Amendment 1): Two doses of SCOV1 (administered on Day 1 and Day 29), followed by two doses of SCOV2 (not before Days 113 and 141 [doses 4 weeks apart]). A final end of study assessment will then be performed 6 weeks after last dose of study vaccine (Day 183).
Participants enrolled under protocol Amendment 2: Vaccine Naive and Previously Vaccinated participants: Two doses of SCOV2 (administered on Day 1 and Day 29) with a final end of study assessment performed 6 weeks after last dose of study vaccine (Day 71); Previously Infected participants: A single dose of SCOV2 (administered on Day 1) with a final end of study assessment performed 6 weeks after last dose of study vaccine (Day 43)â
So if everything had gone to plan, there should have been some news as the 185 days would have been up in April this year, although we are aware of a slow recruitment process.
That said if there had of been a EUREKA moment in the lab, I imagine news would have leaked out.
So maybe Covidity is not as successful as we want to believe and I am not trying to be a doomster, I am just offering alternative thoughts. To be clear, my opinion is still a âStrong buyâ as it is the Cancer treatment platforms of SCLP that I invested in, Covidity was a potential bonusâŚ..and still might be despite my negative thoughts.